Japanese initiative on unapproved products bearing fruit
This article was originally published in Scrip
Executive Summary
Japan's effort to improve the availability of drugs for unmet medical needs appears to be paying dividends, with a number of products for serious disorders recently approved or submitted for regulatory review as part of the ongoing government initiative. The developments have come across a wide range of therapeutic areas from oncology through cardiovascular to infections, reflecting the numerous gaps in the availability of common treatments that have been identified under the programme.